Court grants Amarin long-awaited Vascepa exclusivity

Amarin ($AMRN) has finally grabbed the 5-year marketing exclusivity for fish oil pill Vascepa that it's long been seeking. On Thursday, a U.S. district court ruled that it's eligible, setting aside an FDA decision from last February. Shares of the Irish drugmaker soared as much as 44% on the news, Reuters reports. Story

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.